NANoman Anwar

Noman Anwar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Noman Anwar has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Irritable Bowel Syndrome (IBS) and its management by the Unani System of Medicine: A Review

    by Faiyaz Ahmad, Vijay Bhan Singh, Amreen Fatima, Noman Anwar, Mahboob Us Salam, Najmus Sehar

    Background: Irritable Bowel Syndrome (IBS) is a functional gastrointestinal condition that is very common, relapses frequently, and severely lowers a patient's quality of life. IBS is still a treatment issue in contemporary gastroenterology. It is characterized by stomach pain, bloating, and changed bowel habits without any obvious anatomical or biochemical abnormalities. Conventional medicines are often focused primarily at symptomatic relief, frequently providing poor long-term outcomes and raising risks of negative side effects. The Unani system of medicine, an ancient and holistic therapeutic tradition, views functional gastrointestinal diseases from a broad perspective, emphasizing the restoration of Akhlaat (humoral balance). Objectives: This review aims to systematize and explore the management of IBS within the framework of Unani medicine. Methods: Classical Unani literature and contemporary PubMed/Scopus-indexed research on gastrointestinal disorders and Unani formulations were reviewed and synthesized. Results: Important classical conditions that parallel IBS mechanisms are Zalaqul Ama and Ishal-e-Dimaghi. A solid rational foundation for symptom treatment is provided by therapies that target Su-e-Mizaj (altered temperament) and restore Quwwat-e-Masika (retentive faculty). Conclusion: Unani medicine provides a safe, effective, and long-lasting therapeutic paradigm by addressing the disorder's physical and psychological aspects. To further validate these traditional therapies, clinical studies and scientific standards are advised. Keywords: Irritable Bowel Syndrome; Unani Medicine; Gut-Brain Axis, Su-e-Mizaj.

  • Open Access

    Validating Ethnomedicinal Claims of Itrifal Mulayyin in Patients With Ṣudā‘ (NUMC: A-36) (Headache Disorders) – An Open Prospective Clinical Trial

    by Noman Anwar, Kabiruddin Ahmed, Zaheer Ahmed, Athar Parvez Ansari, Farooqui Shazia

    Background: Ṣudā‘ (Headache disorder), an incapacitating neurological disorder, negatively impacts people’s quality of life, productivity, family and social life and poses huge financial constraints. Itrifal Mulayyin, is a widely used Unani medication for the treatment of headache disorders. Aim: The present study evaluates the effectiveness and safety of Itrifal Mulayyin in headache patients to validate its ethnomedicinal claims. Methods: Clinically diagnosed headache patients, who fulfilled the inclusion criteria and were willing to participate in the study were recruited after obtaining a duly signed informed consent form. The study was conducted in compliance with Good Clinical Practices (GCP) guidelines, with due approval by the Institutional Ethics Committee. Patients received 7g of Itrifal Mulayyin, orally once daily at bedtime for 7 days. Clinical pathology and biochemistry were done to evaluate the medication safety, alongside monitoring adverse occurrences. The Visual Analogues Scale (VAS) was used to assess the efficacy of the formulation. Results: Twenty of 106 recruited patients were unable to take the test, while 86 patients completed the trial. The mean age of the study population was 35.3 years and the majority of them (70.9%) were female. The overall response to treatment was found to be 85%. After 7 days of treatment with Itrifal Mulayyin, a statistically significant (P<0.05) decrease in the mean VAS score was recorded. Pathological and biochemical indices remain normal and no significant change was observed before and after treatment. Throughout the trial, no AE (adverse events) or drug intolerance were reported. Conclusion: The study results affirm the ethnomedicinal claims of the formulation and indicate that Itrifal Mulayyin may be used orally for the efficient treatment of headaches with little to no risk to medication safety.


  • Pharmaceutico-analytical standardization and in vitro anti-diabetic potential of Qurṣ Dhayābīṭus Khāṣ (Unani formulation)- A preliminary scientific appraisal

    by Athar Parvez Ansari, Mary Shamya Arokiarajan, John Christopher, Noman Anwar, N. Zaheer Ahmed, Farooqui Shazia, K. Kabiruddin Ahmed


  • Pharmacognostical Standardization, Phytochemical Evaluation and Contaminants Determination of Ustukhuddūs (Lavandula stoechas Linn) –A Potent Unani Drug

    by Farhath Fathima A, Shariq Shamsi, Mohammed Irfhan N, Zaheer Ahmed N, Jaculin Raiza, Mageswari S, Noman Anwar

    Ustukhuddūs (Lavandula stoechas Linn) is a widely acknowledged drug and has long been used in Unani Medicine for the mitigation of varied ailing conditions. The standardization and quality control parameters of the species are poorly understood, despite its enormous therapeutic values. The current study aims to produce a thorough report on the standardization parameters and quality control analysis of the aerial part of L. stoechas Linn. Standard methods were employed to determine the pharmacognostic, physico-chemical parameters, and preliminary phytochemical screening of the drug. A solvent system containing Toluene: Ethyl acetate: Formic acid (7.6: 2.4: 0.01 v/v) was utilized for qualitative HPTLC analysis to assure the presence of various active components. Atomic absorption spectrophotometer was used for heavy metal analysis, and microbial limit was determined following standard guidelines. The pharmacognostic and phytochemical analysis of aerial part of L. stoechas showed several diagnostic features in the species. The moisture content was found to be very low in the test drug and the total ash value of the drug was recorded to be approximately 4 – 5 times higher than the values of water soluble and acid insoluble ash. The aqueous extract showed higher extractive value when compared with organic extracts. The pH of the test drug was found to be slightly acidic. Phytochemically alkaloid, flavonoid, saponin, tannin, glycosides, terpenoids, steroids, phenols, quinones, coumarins, proteins, and carbohydrates were identified in the drug. The HPTLC chromatogram of chloroform extract showed a greater number of spots in absorbance mode, whereas in fluorescence mode, ethanol extract showed more number of spots. The contaminants determination revealed the presence of potentially toxic metals and microbial load within permissible limits. The comprehensive pharmacognostic profile of L. stoechas Linn reported in this study may complement the available information and may prove valuable for accurately identifying and authenticating the species for future research.


  • Open Access

    Appetite-inducing effect and safety evaluation of Habb-e-Hilteet in patients with Ḍu‘f al-Ishtihā (anorexia): An open prospective clinical trial

    by Noman Anwar, Noor Zaheer Ahmed, Shahida Begum, Athar Parvez Ansari, Ammu Jayanthi Viswanathan

    Objectives: Anorexia is one among the most prevalent conditions triggering malnutrition, drastic weight loss and serious health issues in people especially older adults. Habb-e-Hilteet is commonly prescribed Unani pharmacopoeial formulation for anorexia. However, no scientific data is available as to its safety and efficacy. The current study assessed the appetite-inducing effect and safety of Habb-e-Hilteet in Ḍu‘f al-Ishtihā (anorexia) patients. Methods: An open prospective clinical trial was carried out in 95 clinically diagnosed anorexia patients of either gender (19-65 yrs old). The study was approved by Institutional ethic committee and conducted in accordance with the GCP guidelines. Habb-e-Hilteet, 1 pill (500mg) was administered orally in patients twice daily for 14 days. The safety of the formulation was assessed by important pathological and biochemical indices and monitoring adverse events. The efficacy was assessed on the basis of improvement in the Simplified Nutritional Appetite Questionnaire (SNAQ) score. Results: Out of 95 patients recruited, 78 completed the trial and 17 patients lost to follow-up. The mean age of patients was 29.8 yrs, with the majority (59.0%) being female. Overall therapeutic response was found to be 96%. A significant (PConclusion: The study results indicate that Habb-e-Hilteet could be a viable treatment option for anorexia with no safety concerns. Keywords: Ḍu‘f al-Ishtihā; Buṭlān al-Shahwa; Anorexia; Habb-e-Hilteet; Unani pharmacopoeal formulation.


  • Arq Ajīb – a wonder Unani formulation for inhibiting SARS-CoV-2 spike glycoprotein and main protease – an in silico approach

    by N. Zaheer Ahmed, G. Dicky John Davis, Asim Ali Khan, Lavanya Prabhakar, Meena Ram Paratap, Zeba Afnaan, Meera Devi Sri, Noman Anwar

    Objectives: The current pandemic caused by Severe Acute Respiratory Syndrome Corona-Virus 2 (SARS-CoV-2) has become a global health menace with significant morbidity and mortality besides huge socioeconomic implications. Despite the approval of few vaccines for the prevention of the disease, the discovery of safe and effective countermeasures especially from natural sources is of paramount importance, as the number of cases continues escalating. Arq Ajīb has long been used for various diseases and its ingredients have been reported for antiviral, antimicrobial, antipyretic, anti-inflammatory, antioxidant activities. The present study investigates the inhibitory effect of phytocompound of Arq Ajīb on potential drug targets of SARS-CoV-2. Methods: The structures of phytocompounds present in Arq Ajīb were retrieved from PubChem database and some were illustrated using Marvin Sketch. SARS-CoV-2 S glycoprotein (PDB ID: 6LZG) and 3CL pro (PDB ID: 7BQY) were selected as the target protein. Dock Prep module in UCSF Chimera software was used for receptor structure processing. AutoDock Vina was used to calculate the binding affinities between the protein and ligands and to predict most promising compounds with best scores. Results: Molecular docking results predicted that the phytocompounds of Arq Ajīb had good binding affinity and interaction with S glycoprotein and 3CL pro . Quercetin and Isorhoifolin from Mentha arvensis were identified as promising candidates with the potential to interact with 3CL pro and spike glycoprotein and inhibit the viral replication and its entry into the host. Conclusions: Arq Ajīb may prove valuable for developing novel therapeutic candidate for COVID-19; however, it has to be substantiated further with in-vitro and in-vivo studies.


  • Open Access

    In-Silico Evaluation of Tiryaq-E-Wabai, an Unani Formulation for its Potency against SARS-CoV-2 Spike Glycoprotein and Main Protease

    by N Zaheer Ahmed, Dicky John Davis, Noman Anwar, Asim Ali Khan, Ram Pratap Meena, Zeba Afnaan, Meera Devi

    COVID-19 was originated in Wuhan, China, in December 2019 and has been declared a pandemic disease by WHO. The number of infected cases continues unabated and so far, no specific drug approved for targeted therapy. Hence, there is a need for drug discovery from traditional medicine. Tiryaq-e-Wabai is a well-documented formulation in Unani medicine for its wide use as prophylaxis during epidemics of cholera, plague and other earlier epidemic diseases. The objective of the current study is to generate in-silico evidence and evaluate the potency of Tiryaq-e-Wabai against SARS-CoV-2 spike (S) glycoprotein and main protease (3CLpro). The structures of all phytocompounds used in this study were retrieved from PubChem database and some were built using Marvin Sketch. The protein structure of the SARS-CoV-2 S glycoprotein and 3CLpro was retrieved from the PDB ID: 6LZG and 7BQY respectively. AutoDock Vina was used to predict top ranking poses with best scores. The results of the molecular docking showed that phytocompounds of Tiryaq-e-Wabai exhibited good docking power with spike glycoprotein and 3CLpro. Among tested compounds Crocin from Zafran and Aloin A from Sibr showed strong binding to spike glycoprotein and 3CLpro respectively. Molecular dynamics simulation confirmed the stability of the S glycoprotein-Crocin and 3CLpro-Aloin A complexes. The Unani formulation Tiryaq-e-Wabai has great potential to inhibit the SARS-CoV-2, which have to be substantiated with further in-vitro and in-vivo studies. Keywords: In-silico study, SARS-CoV-2, Tiryaq-e-Wabai, Unani formulation, Crocin, Aloin A


  • Open Access

    Plausible role of Arq Ajīb in combating COVID-19: A multi-faceted review

    by Noman Anwar, N. Zaheer Ahmed, Shehnaz Begum

    The current pandemic caused by SARS-CoV-2 has led to a massive change in every aspect of our lives. It has grossly affected the healthcare system, business and world trade, disruption of movement and supply of essential goods and has crippled the global economy. Although few vaccines have been approved for the control of disease, targeted therapy options for this virulent disease still remain limited and elusive. Exhaustive search for potent therapeutic candidate is in progress, for which herbal armory are also being explored. Medicinal plants and their products play a vital role in alleviating various diseases and have been reported to exhibit a wide range of biological activities. Plant-based drugs with antiviral, anti-inflammatory and immunomodulotry activities were hypothetically considered as potential drugs to prevent and mitigate the prevailing situation caused by SARS-CoV-2. Arq Ajīb ‘a Unani formulation’ presents compelling approach in treating numerous diseases. The ingredients of Arq Ajīb and their phytocompounds have been reported for wide-ranging pharmaco-biological activities including antiviral, anti-inflammatory, immunomodulotry, anti-allergic, antitussive and bronchodilatory activities. Scientific data available on the formulation ingredients and their phytocompounds indicates that the formulation may have a significant role in augmenting the immune status of individual, protecting them from infection and providing symptomatic relief to patients affected with COVID-19. Hence, it may be considered as a potential drug for the development of novel therapeutic candidate for SARS-CoV-2 infection. This multi-faceted review highlights the therapeutic significance and pharmacological actions of Arq Ajīb and its ingredients to demonstrate the plausible role of the formulation in combating COVID-19. Keywords: Arq Ajīb, COVID-19, Pudina, Ajwain, Camphor, Unani formulation